Clinical Trial Update: TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TAC-T cells targeting Claudin 18.2 in metastatic solid tumors (TACTIC-3), a Phase 1/2 study. The trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• TAC-T cells

Snippet

Sponsor: Triumvira Immunologics, Inc. | Conditions: Metastatic Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING